Published in Cancer Gene Therapy Week, June 14th, 2004
"We report in a murine model of acute lymphoid leukemia L1210 the potent antitumor efficiency of a combinatorial delivery of pro-interleukin (IL)-18 gene modified L1210 (Lp18) and IL-1beta converting enzyme (ICE) gene modified L1210 (LpICE). Live leukemia cells Lp18 or Lp18 plus LpICE showed apparently reduced leukemo-genicity with a survival rate of 40% or 50% at 50 days after intraperitoneal (i.p) inoculation of a lethal dose of cells, respectively." researchers in the Peoples Republic of China report.
"Combination of Lp18 and LpICE was capable of inhibiting accumulation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.